Roivant Sciences director Gold sells over $51 million in company stock By Investing.com

In a series of transactions, Daniel Allen Gold, a director at Roivant Sciences Ltd. (NASDAQ:), sold a significant portion of his holdings in the company, totaling over $51 million. The sales occurred between September 24 and September 26, with prices ranging from $11.625 to $11.82 per share.

The first set of transactions took place on September 24, where Gold sold 1,565,670 shares at $11.625 each, followed by an additional 577,186 shares at the same price. On the following day, he continued to divest, selling 991,593 shares at $11.7653 each and 365,551 shares at the same price. The selling spree concluded on September 26 with the sale of 876,000 shares at $11.82 per share.

These transactions resulted in a total sale value of $51,820,727, marking a substantial reduction in Gold’s direct and indirect holdings in Roivant Sciences. Post-transaction, Gold’s direct ownership stood at 5,723,423 shares, with an additional 2,079,059 shares held indirectly through trusts and estate planning vehicles established by him. Furthermore, Gold is associated with QVT Financial Investment Cayman Ltd., which indirectly held 23,055,358 shares after the transactions.

It should be noted that despite the large volume of sales, Gold disclaims beneficial ownership of the shares held indirectly except to the extent of his pecuniary interest. This disclaimer is standard for individuals in similar positions who may have voting and investment control over securities held by trusts or other entities but do not claim full beneficial ownership.

Investors and market watchers often pay close attention to insider transactions such as these for insights into executive sentiment and potential future performance of a company’s stock. However, it is important to remember that such sales can be motivated by a variety of personal financial planning considerations and do not necessarily reflect a negative outlook on the company’s future by the insider.

In other recent news, Roivant Sciences has made significant strides with a major deal to sell its Dermavant subsidiary to OGN for an estimated $1.2 billion, including upfront and future milestone payments, and royalties on future sales of Vtama. The deal is structured to provide Roivant with approximately $500 million in the near term. Goldman Sachs, H.C. Wainwright, and TD Cowen have maintained their ‘Buy’ ratings on Roivant Sciences, while BofA Securities raised its price target to $12.50, maintaining a neutral rating.

Roivant’s subsidiary, Pulmovant, has shown progress with its Phase 2-ready asset mosliciguat for patients with pulmonary hypertension in interstitial lung disease, demonstrating a 38% reduction in pulmonary vascular resistance. Another subsidiary, Immunovant (NASDAQ:), reported positive outcomes from its Phase 2a trial of batoclimab, a treatment for Graves’ Disease.

In addition to these developments, Roivant Sciences reported $18.4 million in product revenue and held a robust $5.7 billion in cash and cash equivalents. The company’s Annual General Meeting resulted in the re-election of directors and the ratification of Ernst & Young LLP as the company’s independent auditor. These recent developments highlight Roivant Sciences’ ongoing efforts to advance its portfolio and financial standings.

InvestingPro Insights

As Roivant Sciences Ltd. (NASDAQ:ROIV) sees notable insider trading with Daniel Allen Gold’s sale of company shares, investors are keen on understanding the financial health and future prospects of the company. According to InvestingPro data, Roivant Sciences holds a market capitalization of approximately $8.7 billion, indicating its significant presence in the market. Despite this, the company’s P/E ratio as of the last twelve months stands at a striking -128.17, suggesting that investors are expecting future earnings to justify the current share price.

The company’s revenue growth has been impressive, with a 101.44% increase over the last twelve months leading up to Q1 2023, and an even more remarkable quarterly revenue growth of 154.96% for Q1 2023. This suggests that Roivant Sciences is expanding its revenue streams at a rapid pace, which could be an attractive point for potential investors. However, it’s important to note the substantial negative gross profit margin and operating income margin, which stand at -230.59% and -655.64% respectively, indicating current challenges in profitability.

Considering these metrics, two InvestingPro Tips that may be particularly relevant to investors are that Roivant Sciences holds more cash than debt on its balance sheet and that the stock generally trades with low price volatility. These factors can provide some assurance regarding the company’s financial stability and the potential for steady investment returns.

For those seeking more comprehensive analysis and additional insights, InvestingPro offers further tips on Roivant Sciences, including details on share buybacks, cash holdings, and analysts’ earnings revisions. Visit https://www.investing.com/pro/ROIV to explore the full list of over 10 InvestingPro Tips available for Roivant Sciences.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.